Pam Cheng, chief operating officer at AstraZeneca, said that the company will have 200 million doses of its candidate vaccine, which it developed in cooperation with the University of Oxford, by the end of 2020, and that 700 million doses will be ready worldwide by the end of Q1 of 2021.
She added in a press briefing that 20 million doses will be available in Britain by the end of the year and 70 million by the end of Q1, 2021.